Glaucoma is the second leading cause of irreversible blindness worldwide, affecting one in two hundred people aged fifty and younger, and one in ten people over the age of eighty. The major risk factor for glaucoma is elevated intraocular pressure (TOP), which contributes to significant damage of the optic nerve and loss of retinal ganglion cells (RGCs). When left untreated, glaucoma leads to the permanent damage of the optic nerve and visual field loss, which often progresses into irreversible blindness. Current treatment to lower intraocular pressure involves eye drops or surgical intervention; however, treatment is ineffective in stopping its progression to vision loss. New and effective strategies are necessary for early detection and treatment of glaucoma.
This invention provides a potent and effective therapeutic alternative for the treatment of glaucoma by inhibiting key players in the autoimmune response leading to intraocular pressure (TOP).